CINECA IRIS Institutional Research Information System

PELLICANO, Rinaldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.405
EU - Europa 5.375
AS - Asia 4.055
SA - Sud America 593
AF - Africa 216
OC - Oceania 182
Continente sconosciuto - Info sul continente non disponibili 15
Totale 20.841
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.015
IT - Italia 1.505
CN - Cina 1.384
SG - Singapore 650
IE - Irlanda 535
DE - Germania 453
SE - Svezia 405
GB - Regno Unito 404
TR - Turchia 354
FR - Francia 297
ES - Italia 269
PL - Polonia 258
ID - Indonesia 257
VN - Vietnam 257
IN - India 252
JP - Giappone 250
BR - Brasile 231
UA - Ucraina 184
CA - Canada 182
AT - Austria 166
AU - Australia 163
MX - Messico 161
KR - Corea 134
CO - Colombia 118
RU - Federazione Russa 115
FI - Finlandia 112
NL - Olanda 107
EG - Egitto 102
IR - Iran 94
HK - Hong Kong 91
CH - Svizzera 79
CL - Cile 76
RO - Romania 69
TW - Taiwan 69
BE - Belgio 65
AR - Argentina 61
GR - Grecia 61
PT - Portogallo 59
PE - Perù 56
CZ - Repubblica Ceca 51
HU - Ungheria 40
DK - Danimarca 34
IL - Israele 33
PK - Pakistan 33
TH - Thailandia 33
SA - Arabia Saudita 27
MY - Malesia 24
EC - Ecuador 23
PH - Filippine 22
ET - Etiopia 21
NO - Norvegia 20
KE - Kenya 19
IQ - Iraq 18
NZ - Nuova Zelanda 18
ZA - Sudafrica 17
PA - Panama 16
EU - Europa 13
LT - Lituania 13
MA - Marocco 13
VE - Venezuela 13
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
BG - Bulgaria 11
HR - Croazia 11
BD - Bangladesh 9
JO - Giordania 9
NG - Nigeria 9
RS - Serbia 9
CU - Cuba 8
GT - Guatemala 8
KZ - Kazakistan 7
UY - Uruguay 7
UZ - Uzbekistan 7
CR - Costa Rica 6
DZ - Algeria 6
EE - Estonia 6
SK - Slovacchia (Repubblica Slovacca) 6
BO - Bolivia 5
BY - Bielorussia 5
KW - Kuwait 5
LB - Libano 5
LV - Lettonia 5
BA - Bosnia-Erzegovina 4
PS - Palestinian Territory 4
SI - Slovenia 4
CI - Costa d'Avorio 3
GE - Georgia 3
LU - Lussemburgo 3
MO - Macao, regione amministrativa speciale della Cina 3
SD - Sudan 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
GH - Ghana 2
HN - Honduras 2
IS - Islanda 2
KH - Cambogia 2
NI - Nicaragua 2
NP - Nepal 2
Totale 20.817
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.472
Chandler 947
Fairfield 753
Santa Clara 602
Dublin 523
Singapore 520
Ashburn 483
Beijing 468
Houston 399
Torino 389
Redwood City 353
Woodbridge 327
Seattle 288
Wilmington 286
Cambridge 276
Jacksonville 267
Dong Ket 155
Medford 152
Princeton 151
Nyköping 148
Columbus 143
Pisa 143
Turin 143
Vienna 134
Jakarta 132
Villeurbanne 127
Dearborn 125
Warsaw 115
Istanbul 91
Shanghai 84
Guangzhou 82
Milan 79
Rome 74
Nanjing 72
Boston 70
San Diego 68
London 58
Hangzhou 57
Fremont 56
New York 54
Tokyo 52
Santiago 50
Helsinki 47
Seoul 47
Bogotá 45
Cairo 44
Barcelona 40
Lima 40
Chengdu 39
Washington 39
Berlin 38
Taipei 38
Wuhan 38
Ottawa 37
Ankara 36
Medellín 34
Boardman 32
Duncan 31
São Paulo 31
Toronto 31
Upper Marlboro 31
Los Angeles 30
Amsterdam 29
Izmir 29
Madrid 29
Buenos Aires 27
Bologna 26
Tehran 26
Central District 25
Hong Kong 25
Jinan 25
Zhengzhou 25
Chicago 24
Frankfurt am Main 24
Hyderabad 24
Norwalk 24
Moscow 23
Prague 23
Sydney 23
Athens 22
Budapest 22
Melbourne 22
Bangkok 20
Naples 20
Brussels 19
Hefei 19
Munich 19
Paris 19
Hebei 18
Pune 18
San Francisco 18
Surabaya 18
Brisbane 17
Hanoi 17
Silver Spring 17
Addis Ababa 16
Bandung 15
Delhi 15
Fuzhou 15
Montreal 15
Totale 12.528
Salva come PNG Salva come JPEG
Nome #
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.824
Proctitis: a glance beyond inflammatory bowel diseases 1.103
Eosinophilic colitis: clinical review and 2020 update 610
The gut and the Inflammatory Bowel Diseases inside-out: the extra-intestinal manifestations 538
A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of nonerosive reflux disease-related symptoms 476
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets 348
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study 314
Endocrine manifestations of chronic HCV infection 299
Fecal calprotectin: beyond intestinal organic diseases 298
Adalimumab trough levels predict Crohn's disease clinical course 278
Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients 274
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 273
Gut microbiota and chronic exercise in diabetic patients: not only bacteria 251
Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy 245
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis 234
Current treatment challenges in the COVID-19 pandemic 232
Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience 230
Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score 221
Physiopathology of intestinal barrier and the role of zonulin 216
Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies? 214
Prevalence of infectious agents in patients with systemic sclerosis: Defining the control group 204
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index 202
Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery: What About Celiac Disease? 193
Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message 186
AMOXYCILLIN AND METRONIDAZOLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A 10-YEAR TREND IN TURIN, ITALY 177
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 174
Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome? 173
2013 update on celiac disease and eosinophilic esophagitis 170
Bariatric Surgery and Inflammatory Bowel Disease: a Role for Microbiota? 170
Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")? 166
Prevalence ofHelicobacter pyloriinfection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy 160
Modulation of the gut microbiota: opportunities and regulatory aspects 157
Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp" 154
Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn's disease 154
Does Helicobacter pylori infection increase the risk of adult-onset asthma? 152
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 152
Comments on Sulimani et al.: A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females 151
On Inverse Association between Helicobacter pylori Gastritis and Microscopic Colitis: The European Data 149
How ameliorate the adherence in patients with inflammatory bowel disease? 146
Helicobacter pyloriinfection and asthma: Is there a direct or an inverse association? A meta-analysis 144
Helicobacter pylori and proton pump inhibitor therapy: One diagnostic method is enough? 144
Power Doppler sonography to predict the risk of surgical recurrence of Crohn’s disease 142
Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis 142
Efficacy of infliximab biosimilars in patients with Crohn's disease 141
Is Helicobacter pylori the infectious trigger for headache?: A review 139
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 138
Response to: Comment on "efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients" 137
Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment 137
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis 136
Inflammation in gastrointestinal disorders: prevalent socioeconomic factors 134
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease 134
Helicobacter pylori eradication: poor medical compliance from East to West of the world 133
Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA 133
A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms 133
A 2016 panorama of Helicobacter pylori infection: key messages for clinicians 132
Features of inflammatory bowel disease followed in a second level center in Northern Italy 132
P02.38 | Current practice of Gastroenterologists in the treatment of Helicobacter pylori infection in Italy: data from the Italian Registry on H. pylori treatment 131
Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity 129
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 128
Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients 123
Benefit of supplements in functional dyspepsia after treatment of Helicobacter pylori 121
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 121
Upper GI bleeding in cirrhotic patients: Which method to search for Helicobacter pylori infection? 120
Comment on "Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study" 120
Osteoporosis, osteopenia, and inflammatory bowel disease: lessons from a real‑world study 119
Helicobacter pylori prevalence: Are the data totally reliable? 118
Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018 118
Serum Cytokeratin-18 Levels for Liver Fibrosis Prediction 117
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 115
COVID-19: a user's guide, status of the art and an original proposal to terminate viral recurrence 113
Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis 110
ETIOLOGY OF CHRONIC LIVER DISEASES IN THE NORTHWEST OF ITALY, 1998 THROUGH 2014 109
The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study 108
Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? 107
Endoscopic ultrasound in the preoperative staging of gastric cancer: Key messages for surgeons 105
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 104
Use of reflux finding score and reflux symptom index for the management of laryngopharyngeal lesions: a pilot study 103
P. 11.17: The Role of Adherence to Therapy on the Outcome in Inflammatory Bowel Disease 99
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 99
P. 04.8 ROLE OF BACTERIAL OVERGROWTH IN CROHN'S DISEASE PATIENTS WITH ILEOCOLIC RESECTION: GLUCOSE BREATH TEST EVALUATION 97
Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results 96
Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases 96
Efficacy of amoxycillin and clarithromycin-based triple therapy for Helicobacter pylori eradication: a 10-year trend in Turin, Italy 96
A dive into the stem cells world 95
Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis 94
A question about dyspeptic patients analyzed using psychometric scores 93
Noncardiac chest pain: a 2018 update 93
Prevalence and prognostic value of hepatic histological alterations in patients with Crohn's disease 92
The first-line treatment of Helicobacter pylori infection in Piedmont in the year 2017 91
Management of inflammatory bowel disease during COVID-19 pandemic 87
Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis 87
The role of hepatic enzymes in Crohn’s disease 86
Irritable bowel syndrome: the clinical approach 86
Infections and stroke: Which potential pathogenic mechanism? 86
CURRENT PRACTICE OF GASTROENTEROLOGISTS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT 85
Causes of childhood epilepsy: a look for celiac disease? 84
Inflammation: a highly conserved, Janus-like phenomenon—a gastroenterologist’ perspective 83
P. 11.11 HELICOBACTER PYLORI IN CELIAC DISEASE AND IN DUODENAL INTRAEPITHELIAL LYMPHOCYTOSIS: A RETROSPECTIVE STUDY 82
History of Inflammatory Bowel Diseases 81
Elastography for characterization of focal liver lesions: current evidence and future perspectives 81
Totale 18.507
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.013
article - articoli 0
book - libri 0
conference - conferenze 2.411
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.424
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.685 0 0 0 0 0 0 239 318 358 311 203 256
2020/20213.199 190 294 331 254 233 336 224 210 217 274 211 425
2021/20224.313 239 166 179 250 226 233 726 658 510 248 446 432
2022/20234.014 329 299 203 287 369 721 392 300 489 159 264 202
2023/20242.771 256 305 187 247 269 285 163 285 19 212 235 308
2024/20252.466 169 252 303 399 991 345 7 0 0 0 0 0
Totale 21.470